Lorna B. Jarvis

Lorna B. Jarvis

Auto-generated profile, based on publicly available information

Lorna B. Jarvis

University of Cambridge

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 May 2022 in Science
Verified
Journal Article
Open access
CCC. Domínguez Conde
C. Domínguez Conde
CXC. Xu
C. Xu
LJL. B. Jarvis
L. B. Jarvis
DRD. B. Rainbow
D. B. Rainbow
SWS. B. Wells
S. B. Wells
STS. A. Teichmann
S. A. Teichmann
Despite their crucial role in health and disease, our knowledge of immune cells within human tissues remains limited. We surveyed the immune compartment of 16 tissues from 12 adult donors by single-cell RNA sequencing and VDJ sequencing generating a dataset of ~360,000 cells. To systematically resolve immune cell heterogeneity across tissues, we developed CellTypist, a machine learning tool for rapid and precise cell type annotation. Using this approach, combined with detailed curation, we determined the tissue distribution of finely phenotyped immune cell types, revealing hitherto unappreciated tissue-specific features and clonal architecture of T and B cells. Our multitissue approach lays the foundation for identifying highly resolved immune cell types by leveraging a common reference dataset, tissue-integrated expression analysis, and antigen receptor sequencing.

17 February 2020 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
KJKylie Renee James
Kylie Renee James
TGTomas Gomes
Tomas Gomes
RERasa Elmentaite
Rasa Elmentaite
NKNitin Kumar
Nitin Kumar
EGEmily L. Gulliver
Emily L. Gulliver
STSarah A. Teichmann
Sarah A. Teichmann

13 August 2025 in Nature Immunology
Verified
Journal Article
Open access
SWSteven B. Wells
Steven B. Wells
DRDaniel B. Rainbow
Daniel B. Rainbow
MMMichal Mark
Michal Mark
PSPeter A. Szabo
Peter A. Szabo
CECan Ergen
Can Ergen
NYNir Yosef
Nir Yosef
The immune system comprises multiple cell lineages and subsets maintained in tissues throughout the lifespan, with unknown effects of tissue and age on immune cell function. Here we comprehensively profiled RNA and surface protein expression of over 1.25 million immune cells from blood and lymphoid and mucosal tissues from 24 organ donors aged 20–75 years. We annotated major lineages (T cells, B cells, innate lymphoid cells and myeloid cells) and corresponding subsets using a multimodal classifier and probabilistic modeling for comparison across tissue sites and age. We identified dominant site-specific effects on immune cell composition and function across lineages; age-associated effects were manifested by site and lineage for macrophages in mucosal sites, B cells in lymphoid organs, and circulating T cells and natural killer cells across blood and tissues. Our results reveal tissue-specific signatures of immune homeostasis throughout the body, from which to define immune pathologies across the human lifespan.

1 February 2018 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
James GristJames Grist
James Grist
LJLorna B. Jarvis
Lorna B. Jarvis
ZGZoya Georgieva
Zoya Georgieva
STSara Thompson
Sara Thompson
HSHarpreet Kaur Sandhu
Harpreet Kaur Sandhu
JJJoanne L. Jones
Joanne L. Jones
Following activation, T cells rapidly divide and acquire effector functions. This energetically demanding process depends upon the ability of T cells to undergo metabolic remodeling from oxidative phosphorylation to aerobic glycolysis, during which glucose is converted into lactate and released extracellularly. In this article, we demonstrate that extracellular lactate can be used to dynamically assess human T cell responses in vitro. Extracellular lactate levels strongly correlated with T cell proliferation, and measuring lactate compared favorably with traditional methods for determining T cell responses (i.e., [3H]thymidine incorporation and the use of cell proliferation dyes). Furthermore, we demonstrate the usefulness of measuring lactate as a read-out in conventional suppression assays and high-throughput peptide-screening assays. Extracellular lactate was stably produced over 7 d, and results were reproducibly performed over several freeze–thaw cycles. We conclude that the use of extracellular lactate measurements can be a sensitive, safe, stable, and easy-to-implement research tool for measuring T cell responses and cellular metabolic changes in vitro.

14 October 2021 in Communications Biology
Verified
Journal Article
Open access
PDF file
LJLorna B. Jarvis
Lorna B. Jarvis
DRDaniel B. Rainbow
Daniel B. Rainbow
VCValerie Coppard
Valerie Coppard
SHSarah K. Howlett
Sarah K. Howlett
ZGZoya Georgieva
Zoya Georgieva
JJJoanne L. Jones
Joanne L. Jones
The adoptive transfer of regulatory T-cells (Tregs) is a promising therapeutic approach in transplantation and autoimmunity. However, because large cell numbers are needed to achieve a therapeutic effect, in vitro expansion is required. By comparing their function, phenotype and transcriptomic profile against ex vivo Tregs, we demonstrate that expanded human Tregs switch their metabolism to aerobic glycolysis and show enhanced suppressive function through hypoxia-inducible factor 1-alpha (HIF1A) driven acquisition of CD73 expression. In conjunction with CD39, CD73 expression enables expanded Tregs to convert ATP to immunosuppressive adenosine. We conclude that for maximum therapeutic benefit, Treg expansion protocols should be optimised for CD39/CD73 co-expression.

20 June 2019 in JCI Insight
Verified
Journal Article
Open access
PDF file
ACAlasdair J. Coles
Alasdair J. Coles
LALaura Azzopardi
Laura Azzopardi
OKOnajite Kousin-Ezewu
Onajite Kousin-Ezewu
HMHarpreet Kaur Mullay
Harpreet Kaur Mullay
STSara A.J. Thompson
Sara A.J. Thompson
JJJoanne L. Jones
Joanne L. Jones
BACKGROUND: The lymphocyte-depleting antibody alemtuzumab is a highly effective treatment for relapsing-remitting multiple sclerosis (RRMS); however, 50% of patients develop novel autoimmunity after treatment. Most at risk are individuals who reconstitute their T cell pool by proliferating residual cells, rather than producing new T cells in the thymus, raising the possibility that autoimmunity might be prevented by increasing thymopoiesis. Keratinocyte growth factor (palifermin) promotes thymopoiesis in nonhuman primates. METHODS: Following a dose tolerability substudy, individuals with RRMS (duration ≤10 years; expanded disability status scale ≤5.0, with ≥2 relapses in the previous 2 years) were randomized to placebo or 180 μg/kg/d palifermin, given for 3 days immediately before and after each cycle of alemtuzumab, with repeat doses at month 1 (M1) and M3. The interim primary endpoint was naive CD4 + T cell count at M6. Exploratory endpoints included number of recent thymic emigrants (RTEs) and signal joint T cell receptor excision circles/ml (sjTRECs/ml) of blood. The trial’s primary endpoint was incidence of autoimmunity at M30. RESULTS: At M6, individuals receiving palifermin had fewer naive CD4 + T cells (2.229 × 10 7 /l vs. 7.733 × 10 7 /l; P = 0.007), RTEs (16% vs. 34%), and sjTRECs/ml (1100 vs. 3396), leading to protocol-defined termination of recruitment. No difference was observed in the rate of autoimmunity between the 2 groups. CONCLUSION: In contrast with animal studies, palifermin reduced thymopoiesis in our patients. These results offer a note of caution to those using palifermin to promote thymopoiesis in other settings, particularly in the oncology/hematology setting, where alemtuzumab is often used as part of the conditioning regime. TRIAL REGISTRATION: ClinicalTrials.gov NCT01712945. FUNDING: MRC and Moulton Charitable Trust.